Québec City Medical Research: Mégie and the Other Pioneers

EP
By
Emily Parker - Travel & Lifestyle Writer
5 Min Read

Québec City is not often thought of as a medical research capital, but for a city of its size the output is serious. The CHU de Québec-Université Laval research centre employs roughly 1,500 researchers and support staff across its five sites, and the total medical and biomedical research funding flowing through Université Laval in 2024 was approximately $210 million. That places the Québec City cluster behind Montréal and Toronto in absolute terms but well ahead of comparable Canadian cities on a per-capita basis.

What sets it apart

Several researchers have shaped the city’s scientific profile over the past three decades. Dr Marie-Françoise Mégie, who ran the palliative care service at the CHU de Québec in the 1990s and early 2000s, became nationally known for her work on end-of-life ethics and was later appointed to the Senate of Canada in 2016. Her research into the sociological dimensions of end-of-life care for Haitian-Canadian patients, published in the Revue canadienne de bioéthique in 2008, remains widely cited in Québec medical training programmes.

The oncology group at the CHU de Québec-Université Laval has been the most productive single research cluster in the city since 2005. Led for a decade by Dr Jean-Guy Lacombe, the group published the pivotal OCTO-GERI trial results in the New England Journal of Medicine in 2019 on treatment protocols for elderly patients with metastatic prostate cancer. The work has changed clinical practice across the Canadian network and has been cited in European and American treatment guidelines.

On the ground

Cardiovascular research, organised around the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ), is the other major biomedical presence. The IUCPQ runs a 200-bed specialist hospital at 2725 Chemin Sainte-Foy and has been the primary Canadian research centre for pulmonary hypertension since the 1980s. Dr Steeve Provencher’s group there has contributed substantially to the global evidence base on pulmonary arterial hypertension treatment protocols.

Neuroscience research is concentrated in two locations. The Centre de recherche CERVO on the Institut de santé mentale site in Beauport focuses on mental health and neurodegenerative disease, with particular strength in Alzheimer’s research. Dr Sonia Lupien’s team, though based primarily in Montréal, runs collaborative work with CERVO on chronic stress and cortisol-related memory deficits. The second cluster, at the Centre de recherche du CHU on the Hôpital de l’Enfant-Jésus site, focuses on traumatic brain injury and has produced clinical guidelines used nationally since 2015.

Infectious disease research has gained visibility since 2020. The Centre de recherche en infectiologie at the CHU de Québec ran a significant share of the Canadian COVID-19 clinical trials, including several vaccine and therapeutic trials at the CHU site. Dr Guy Boivin, the centre director, had been working on respiratory pathogen surveillance for twenty years before the pandemic and was able to pivot the centre’s infrastructure quickly in March 2020.

Worth knowing

The pharmaceutical industry maintains a smaller but real presence. GlaxoSmithKline Biologicals, later acquired and rebranded in the 2010s, operates a vaccine development site on Avenue John F.-Kennedy that produces clinical trial material for a range of conjugate vaccines. The site employs roughly 450 staff. Medicago, a plant-based vaccine biotechnology company that developed a COVID vaccine approved by Health Canada in 2022, was headquartered in Québec City before its closure in 2023.

Funding comes primarily from the Canadian Institutes of Health Research, the Fonds de recherche du Québec en Santé (FRQS), and a mix of industry partnerships and philanthropic support. Per-capita research funding in the Québec City CMA runs about twenty percent above the national average for health research, a figure that has held steady for a decade.

The collection

Public engagement with medical research is unusually strong in Québec City. The Relais pour la vie cancer fundraising event draws roughly ten thousand participants annually, and the CHU de Québec Foundation reported $38 million in philanthropic revenue in 2024. The foundation maintains a public gallery at the CHU Hôtel-Dieu site profiling current research projects in terms accessible to non-specialist visitors.

For a visiting medical professional or researcher, the principal entry points are the CHU de Québec-Université Laval website (for research partnerships), the Faculté de médecine at Université Laval (for academic collaborations), and the annual Congrès médical Dr Marie-Françoise Mégie held each November, which has become the principal medical conference in the city.

Share This Article
EP
Travel & Lifestyle Writer
Emily covers inspiring places, seasonal experiences and practical ideas for making the most of a stay in Québec City.
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *